8-K: Phathom Pharmaceuticals Reports Strong First Quarter Launch of VOQUEZNA, Exceeding 17,500 Prescriptions

Phathom Pharmaceuticals announced its first quarter 2024 financial results, highlighting a successful launch of VOQUEZNA with over 17,500 prescriptions dispensed and $1.9 million in net revenue.

Summary

• Phathom Pharmaceuticals reported its first full quarter of VOQUEZNA product sales, generating $1.9 million in net revenue.
• Over 17,500 prescriptions for VOQUEZNA products have been dispensed since launch, a 361% increase since the last quarterly report.
• Total estimated prescription demand for VOQUEZNA products exceeds 43,000 prescriptions written since launch.
• The prescriber base for VOQUEZNA has grown to over 3,800 unique prescribers, a 215% increase since the last quarterly report.
• Cigna Healthcare has added VOQUEZNA tablets to its formularies, expanding coverage to approximately 48% of all U.S. commercial lives.
• The company launched a national direct-to-consumer campaign, 'VOQUEZNA Can Kick Some Acid', across various media platforms.
• Research and development expenses decreased to $9.4 million, down from $11.5 million in the same quarter last year.
• Selling, general, and administrative expenses increased significantly to $62.0 million, up from $18.6 million in the same quarter last year, due to commercial launch activities.
• The net loss for the quarter was $82.9 million, compared to $37.8 million in the first quarter of 2023.
• The company's cash and cash equivalents were $322.2 million as of March 31, 2024.
• Phathom believes it has sufficient capital to fund operations through the end of 2026.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong launch metrics for VOQUEZNA, but the significant net loss and increased expenses temper the overall sentiment. The company's cash runway and future plans are encouraging.

Positives

• The launch of VOQUEZNA is showing strong momentum with significant growth in prescriptions and prescriber base.
• The addition of Cigna Healthcare to the formulary significantly expands market access.
• The direct-to-consumer campaign is expected to increase brand awareness and drive demand.
• The company has a strong cash position of $322.2 million and believes it has sufficient capital to fund operations through the end of 2026.
• The company is progressing with clinical trials for additional indications of VOQUEZNA.

Negatives

• The company reported a significant net loss of $82.9 million for the quarter, compared to $37.8 million in the same quarter last year.
• Selling, general, and administrative expenses increased substantially to $62.0 million due to commercial launch activities.
• The company is still reliant on third parties for manufacturing and clinical testing.

Risks

• The company's ability to successfully commercialize VOQUEZNA depends on market acceptance and reimbursement levels.
• The company may use its capital resources sooner than expected, requiring additional capital raises.
• Clinical development of vonoprazan carries inherent risks.
• Regulatory approvals for expanded indications are not guaranteed.
• Unexpected adverse side effects or inadequate efficacy of vonoprazan could limit its commercialization.

Future Outlook

Phathom expects both overall demand and total dispensed prescriptions to increase in the coming months as the launch progresses, formulary coverage broadens, and, if approved, VOQUEZNA's label expands to include the treatment associated with symptomatic heartburn for Non-Erosive GERD. The company also anticipates initiating a Phase 3 trial for As Needed dosing of VOQUEZNA for active heartburn episodes and a Phase 2 study for Eosinophilic Esophagitis later this year.

Management Comments

• Terrie Curran, President and CEO of Phathom, stated that they are thrilled with the promising strides made in their first full quarter post-launch of VOQUEZNA.
• Terrie Curran also noted that prescribers are embracing VOQUEZNA as a powerful new treatment option and that demand is rapidly growing.

Industry Context

This announcement highlights Phathom's progress in the competitive gastrointestinal therapeutics market. The successful launch of VOQUEZNA and expansion of formulary coverage positions the company to compete with established treatments like proton pump inhibitors (PPIs). The direct-to-consumer campaign is a common strategy in the pharmaceutical industry to drive patient awareness and demand.

Comparison to Industry Standards

• The 361% increase in prescriptions since the last quarterly report is a strong indicator of market acceptance, exceeding typical launch growth rates for new pharmaceutical products.
• The expansion of coverage to 48% of U.S. commercial lives is a significant achievement, placing Phathom in a competitive position with other pharmaceutical companies in the GI space.
• The company's direct-to-consumer campaign is similar to strategies employed by other pharmaceutical companies launching new drugs, such as AbbVie's Rinvoq campaign or Eli Lilly's Trulicity campaign.
• The reported net loss of $82.9 million is not unusual for a company in the early stages of commercialization, as significant investments are required for marketing and sales infrastructure. This is similar to other companies in the biotech sector during their launch phase, such as Madrigal Pharmaceuticals during the launch of Rezdiffra.
• The cash runway through the end of 2026 is a positive sign, providing financial stability for the company's growth plans. This is comparable to other biotech companies that have recently launched products and have secured sufficient funding for the next few years.

Stakeholder Impact

• Shareholders may be encouraged by the strong launch metrics but concerned about the net loss.
• Employees may be motivated by the company's progress and growth.
• Patients will benefit from increased access to VOQUEZNA.
• Healthcare providers will have a new treatment option for GERD.
• Suppliers and creditors will be impacted by the company's financial performance.

Next Steps

• Phathom will continue to expand formulary coverage for VOQUEZNA.
• The company will continue its direct-to-consumer marketing campaign.
• Phathom will present at Digestive Disease Week (DDW) 2024.
• The company awaits FDA decision on the NDA for VOQUEZNA as a daily treatment for Non-Erosive GERD.
• Phathom plans to initiate a Phase 3 trial for As Needed dosing of VOQUEZNA for active heartburn episodes.
• The company plans to initiate a Phase 2 study for Eosinophilic Esophagitis (EoE).

Key Dates

Keywords

VOQUEZNA, Phathom Pharmaceuticals, GERD, Erosive GERD, Non-Erosive GERD, Gastrointestinal Diseases, Prescriptions, Commercial Launch, FDA, Vonoprazan, PCAB, H. pylori, Formulary, Direct-to-consumer, Clinical Trials